Clinical trials: Anti-obesity Agents
Type 2 Diabetes Mellitus
Gastric Modulator (TANTALUS® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients - a Randomized Control Trial
This study aims to analyze the pre- and post-operative clinical, hormonal and biochemical changes in moderately obese type 2 diabetic patients who are sub-optimally controlled on at least 2 anti-diabetic agents.
- Trial name
- NCT00975533
- Testing
- Tantalus, Insulin
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chinese University of Hong Kong
Overweight, Obesity
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
- Trial name
- NCT00402077
- Testing
- pramlintide acetate, sibutramine, phentermine
- Where
- 16 sites in United States
- Volunteers
- 258 people
- Sponsor
- AstraZeneca
Obesity
Study to Evaluate ARD-101 in Adults With Obesity
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in obese subjects with a body mass index (BMI) of 30-45 kg/m2.
- Trial name
- NCT05121441
- Testing
- ARD-101
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Aardvark Therapeutics, Inc.
Obesity, Nutrition Disorders
Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers
The purpose of this study is to assess the drug concentration of Micafungin amongst healthy volunteers having different weight groups.
- Conditions
- Obesity, Nutrition Disorders, Overweight
- Trial name
- Micafungin (NCT01090141)
- Testing
- Micafungin
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Anti Obesity Agent
Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36
Interaction of GLP-1 and PYY3-36 in the inhibition of food intake in healthy subjects
- Trial name
- NCT00822705
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Metabolism and Nutrition Disorder, Obesity
A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability, efficacy and pharmacokinetics (the rate at which the trial drug is eliminated from the body) of NNC…
- Trial name
- NCT01044108
- Testing
- NNC 0070-0002-0453, '2-0453
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Multiple Sclerosis, Long COVID
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making…
- Conditions
- Multiple Sclerosis, Long COVID, Long Covid19, Obese
- Trial name
- NCT06171152
- Testing
- Liraglutide Pen Injector [Saxenda], Medication Diary
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Obesity, Adolescent Obesity
Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond…
- Conditions
- Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory
- Trial name
- PRESSURE (NCT06575738)
- Testing
- Injectable semaglutide or injectable tirzepatide, Standard postoperative care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Colorado, Denver
Bariatric Surgery, Obesity
Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in subjects at least one year after bariatric surgery (sleeve gastrectomy or gastric bypass).
- Conditions
- Bariatric Surgery, Obesity, Weight Gain
- Trial name
- NCT05215847
- Testing
- ARD-101
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Aardvark Therapeutics, Inc.
Obesity
Zonisamide for Weight Reduction in Obese Adults
The primary aim of this study is to assess long-term weight loss efficacy of zonisamide relative to placebo in obese patients prescribed a dietary intervention.
- Trial name
- NCT00275834
- Testing
- Zonisamide
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Duke University
Obesity and Obesity-related Medical Conditions, Bariatric Surgery
Monitoring Nutritional Consequences of Obesity Treatment on Women's Health
The goal of this observational study is to investigate the long-term effect of obesity treatments on the health of women. This study will specifically focusses on the effects on nutritional intake, nutritional status…
- Conditions
- Obesity and Obesity-related Medical Conditions, Bariatric Surgery, Anti-obesity Agents, Body Composition
- Trial name
- MONUCO (NCT06945016)
- Where
- Netherlands
- Volunteers
- 1,150 people
- Sponsor
- Wageningen University and Research
Sleep Apnea, Obstructive Sleep Apnea
Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients
This RCT explores the efficacy of Zonisamide (Zonegran®)on overweight/obese in patients with moderate to severe obstructive sleep apnea.
- Conditions
- Sleep Apnea, Obstructive Sleep Apnea, Obesity
- Trial name
- NCT01765608
- Testing
- Zonisamide, nCPAP
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Göteborg University
Type 2 Diabetes, Obesity
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
To determine if the EndoBarrier safely and effectively improves glycemic control in obese subjects with type 2 diabetes
- Trial name
- ENDO (NCT01728116)
- Testing
- EndoBarrier
- Where
- 25 sites in United States
- Volunteers
- 325 people
- Sponsor
- Morphic Medical Inc.
Obesity
Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery
This is a randomized controlled trial employing a Sequential Multiple Assignment Randomized Trial (SMART) design to test whether pharmacotherapy, in conjunction with lifestyle counseling, can reverse weight regain after bariatric…
- Trial name
- PROJECT-BARI (NCT05975580)
- Testing
- Topiramate, Phentermine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, Irvine
Overweight and Obesity
Trial to Examine the Effect of Natural Anti- Obesity Agent (Phaseolus Vulgaris) Among Women of Lahore
This double-blind randomized placebo-controlled trial will test the hypothesis that administration of Phaseolus Vulgaris supplementation to women in Lahore, Pakistan, who are overweight will induce the weight loss (Primary…
- Trial name
- PVE-AO (NCT05451927)
- Testing
- Phaseolus Vulgaris
- Where
- 2 sites in Pakistan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hafiza Aisha Sadiqa
Obesity & Overweight
Retrospective Evaluation of Sibutramine-Topiramate Therapy for Obesity in Real-World Outpatient Practice
This retrospective real-world cohort study aims to evaluate the effectiveness, safety, and tolerability of the combination of sibutramine and topiramate in the treatment of obesity and overweight associated with metabolic…
- Trial name
- SIBUTAMATE (NCT07588750)
- Testing
- Sibutramine + Topiramate
- Where
- Brazil
- Volunteers
- 278 people
- Sponsor
- Falquetomed
Hormone-receptor-positive Breast Cancer, Early Breast Cancer
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial
The CLARA trial is a phase II window-of-opportunity trial evaluating how a commonly used weight-loss medication (tirzepatide, a GLP-1/GIP receptor agonist) affects breast cancer biology, alone and in combination with standard…
- Trial name
- CLARA (NCT07676331)
- Testing
- Tirzepatide, Letrozole (Aromatase Inhibitors)
- Volunteers
- 168 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Overweight, Obesity
Safety and Efficacy of Medicinal Plant Extract in Overweight and Obese Participants.
The purpose of this randomized , double -blind clinical trial is to evaluate the efficacy and safety of a daily administration of Nitraria retusa extract in overweight and obese participants, during 10 days.
- Trial name
- NCT05824039
- Testing
- Tea infusion
- Where
- Tunisia
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Laouani Aicha
Cocaine Use Disorders
A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence
The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, bupropion and naltrexone, as a pharmacotherapy for cocaine dependence.
- Trial name
- NCT01739192
- Testing
- Bupropion
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Craig Rush
Overweight and Obesity, Hypercholesterolemia
Effect of Silibinin(A) as a Potential Anti-obesity Agent
Our preliminary reports have found in silico and in vitro that the milk thistle derivative Silibinin(A) is able to inhibit pancreatic lipase, in a similar way that the classical anti-obesity drug orlistat.
- Conditions
- Overweight and Obesity, Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT05069298
- Testing
- Silibinin A
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad Católica San Antonio de Murcia